## ZM323881

®

MedChemExpress

Cat. No.:	HY-15467		
CAS No.:	193001-14-8	F_ //	
Molecular Formula:	C <sub>22</sub> H <sub>18</sub> FN <sub>3</sub> O <sub>2</sub>		
Molecular Weight:	375.4	HN OH	
Target:	VEGFR		
Pathway:	Protein Tyrosine Kinase/RTK	Ŭ Ŭ Ŭ N	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	~	

BIOLOGICAL ACTIVITY					
BIOLOGICAL ACTIVITY					
Description	ZM323881 is a potent and selective VEGFR2 inhibitor with an IC $_{50}$ of less than 2 nM.				
IC <sub>50</sub> & Target	VEGFR2 2 nM (IC <sub>50</sub> )				
In Vitro	ZM323881 is an anilinoquinazoline that potently inhibits VEGFR2 (KDR) tyrosine kinase activity anddemonstrates excellent selectivity versus other receptor tyrosine kinases, including PDGFRβ, FGFR1, EGFR and erbB2 (IC <sub>50</sub> >50 µM). ZM323881 inhibits VEGF-A-induced endothelial cell proliferation(IC <sub>50</sub> =8 nM) and VEGFR2 tyrosine phosphorylation <sup>[1]</sup> . ZM323881 inhibits activation of VEGFR-2, but not of VEGFR-1, epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), or hepatocyte growth factor (HGF) receptor. In HAECs, ZM323881 completely inhibits VEGF-induced ERK phosphorylation at 1 µM <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

Ρ		<b>T</b>	$\frown$	$\mathbf{c}$		
12	•					
	9		9	-	9	

Kinase Assay <sup>[1]</sup>	Compounds (ZM323881) are incubated (20 minutes, room temperature) with enzyme in an N-2-hydroxyethylpiperazine-N'-2- ethanesulphonate (HEPES) (pH 7.5) buffered solution containing 10 mM MnCl <sub>2</sub> and 2 µM ATP, in96-well plates coated with a poly(Glu, Ala, Tyr) 6:3:1 random copolymer substrate. Phosphorylated tyrosine is then detected bysequential incubation with mouse IgG anti-phosphotyrosine antibody a horseradish peroxidase(HRP)-linked sheep anti-mouse Ig antibody and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid). IC <sub>50</sub> data are interpolated by nonlin-ear regression <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay <sup>[1]</sup>	HUVEC cells isolated from umbilical cords are plated (at passage 2–8) in 96-wellplates (1000 cells/well) and dosed with ZM323881±VEGF-A (3 ng/mL), EGF (3 ng/mL), or basicfibroblast growth factor (bFGF, 0.3 ng/mL). The cultures are then incubated for 4 days. On day 4, the cultures are pulsed with 1 μCi/well of <sup>3</sup> H-thymidine and reincubated for 4 hours. The cells are then harvested and assayed for the incorporation of tritium by using a beta-counter. IC <sub>50</sub> data are interpolated <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

## Product Data Sheet

- Front Physiol. 2018 Nov 30;9:1718.
- Oncotarget. 2016 Sep 27;7(39):63839-63855.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Whittles CE, et al. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation. 2002 Dec;9(6):513-22.

[2]. Endo A, et al. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF. J Recept Signal Transduct Res. 2003;23(2-3):239-54.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA